Generic Name and Formulations:
Edoxaban 15mg, 30mg, 60mg; tabs.
Indications for SAVAYSA:
To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5–10 days of initial therapy with parenteral anticoagulant.
Limitations Of use:
Not for use in NVAF patients with CrCl >95mL/min.
Assess CrCl prior to initiation. NVAF: CrCl >50mL/min: 60mg once daily; CrCl 15–50mL/min: 30mg once daily. DVT/PE: CrCl >50mL/min: 60mg once daily following initial parenteral anticoagulant; CrCl 15–50mL/min, body wt. ≤60kg, or concomitant P-gp inhibitors: 30mg once daily. Transition to or from Savaysa: see full labeling.
Active pathological bleeding.
Reduced efficacy in nonvalvular atrial fibrillation (NVAF) patients with CrCl >95mL/min. Premature discontinuation increases the risk of ischemic events. Spinal/epidural hematoma.
Reduced efficacy in NVAF patients with CrCl >95mL/min; use another anticoagulant. Premature discontinuation increases risk of ischemic events; if discontinued for reason other than bleeding or therapy completion, consider coverage with another anticoagulant. Increased risk of spinal/epidural hematoma in anticoagulated patients receiving neuraxial anesthesia or undergoing spinal puncture (eg, use of indwelling epidural catheters); monitor for signs/symptoms of neurological impairment. Increased risk of bleeding; monitor for signs/symptoms of blood loss; discontinue if active pathological hemorrhage occurs. Patients with mechanical heart valves or moderate-to-severe mitral stenosis: not recommended. Discontinue at least 24hrs before surgery. Renal impairment (CrCl <15mL/min), moderate or severe hepatic impairment (Child-Pugh B and C): not recommended. Labor & delivery. Pregnancy. Nursing mothers: not recommended.
Factor Xa inhibitor.
Increased risk of bleeding with concomitant aspirin, other antiplatelets or antithrombotic agents, fibrinolytic therapy, chronic NSAIDs, SSRIs, and SNRIs; monitor. Concomitant other anticoagulants in long term therapy: not recommended. Avoid concomitant P-gp inducers (eg, rifampin).
Bleeding (may be serious or fatal), anemia, rash, abnormal LFTs.
Tabs 15mg—30; 30mg, 60mg—30, 90, 500
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Examining the Efficacy of Different Oxygen Flow Rates for Cluster Headache Attacks
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- Daily Alcohol Use May Drive Chronic Pain in Adults With HIV
- Tools to Address the Opioid Crisis
- AHA/ACC Release Updated Guidelines for Cholesterol Management
- Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain